Incretin & mitochondrial research
Most studiedRetatrutide
Triple agonist of GLP-1, GIP and glucagon receptors
VY-RET-2609-02Tested 2026-09-18
Purchase options
Price
$135
AUD · GST inclusive · $13.50 per mg
Quantity
1
Same-day dispatch
Orders before 2pm AEST
Tracked express post
Australia Post, 1–3 business days
Discreet packaging
Plain, unbranded outer box
Description
Retatrutide is a single-molecule triple agonist engineered to act on the GLP-1, GIP and glucagon receptors simultaneously. In published research it is examined for its effects on energy expenditure, hepatic fat and glycaemic markers. Supplied as a lyophilised powder for in-vitro and laboratory use.
Research notes
- Balanced receptor activity across all three incretin and glucagon pathways
- Studied in multi-week metabolic models with weekly dosing intervals
- Reconstitute with bacteriostatic water; stable 28 days refrigerated once in solution
Research use only. This compound is supplied for in-vitro and laboratory research. It is not approved by the TGA or any regulatory body for human or veterinary use. Not for human consumption. Handle with appropriate laboratory precautions.
Specifications
- Purity (independent)
- 99.42%
- Molecular formula
- C221H342N46O68
- Molar mass
- 4731.3 g/mol
- CAS number
- 2381089-83-2
- Form
- Lyophilised powder
- Storage
- −20 °C, protect from light
- Batch
- VY-RET-2609-02
- Last tested
- 2026-09-18
